JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB8327

Anti-HIV protease antibody [1696]

Be the first to review this product! Submit a review

|

(8 Publications )

Mouse Monoclonal POL antibody. Suitable for Dot and reacts with Synthetic peptide samples. Cited in 8 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human immunodeficiency virus type 1 BH10 gag-pol.
1 Images
Dot Blot - Anti-HIV protease antibody [1696] (AB8327)
  • Dot

Supplier Data

Dot Blot - Anti-HIV protease antibody [1696] (AB8327)

Dot blot analysis of ab8327. The total amount of ab8327 spotted on the nitrocellulose membrane are indicated in left column.

Lane 1 : ab8327; 0.2 μg/ml

Lane 2 : ab8327; 1.0 μg/ml

Lane 3 : ab8327; 2.0 μg/ml

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

1696

Isotype

IgG1

Carrier free

No

Applications

Dot

applications

Immunogen

Recombinant Full Length Protein corresponding to Human immunodeficiency virus type 1 BH10 gag-pol.

P03366

Specificity

The antibody recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2). The antibody does not react with the precursor.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Synthetic peptide": { "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.098% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HIV protease also known as aspartyl protease or protein catabolite is an enzyme vital for the maturation of the HIV virus. It is a homodimer each monomer having a mass of about 11 kilodaltons contributing to a total mass of roughly 22 kilodaltons. This enzyme is specifically expressed in HIV-infected cells where it plays a critical role in the life cycle of the virus. HIV protease cleaves newly synthesized polyproteins at specific sites to create the mature protein components of the infectious HIV particle.
Biological function summary

HIV protease is essential for the production of functional viral proteins facilitating viral particle assembly. It is not part of a larger complex but acts on its own to ensure correct protein maturation. Without the activity of this protease the virus cannot replicate efficiently as it fails to produce infectious viral particles. This makes HIV protease an ideal target for antiretroviral drugs which aim to inhibit its function and hinder the progression of the virus.

Pathways

The HIV protease plays a core role in the viral replication and maturation pathway essential for generating infectious virions. It interacts directly with the gag and gag-pol polyprotein precursors cleaving them into functional units necessary for structural components and replication machinery of the virus. Besides its action upon these precursor proteins integrates it tightly into the intricate machinery of HIV's lifecycle ensuring that all viral components become functionally active for subsequent infections.

HIV protease is intimately associated with the Human Immunodeficiency Virus (HIV) infection that leads to Acquired Immunodeficiency Syndrome (AIDS). This enzyme represents a critical target for antiretroviral therapy including protease inhibitors which aim to block its activity and viral replication. The enzyme's inhibition reduces viral load therefore managing the progression of the disease. Moreover resistance mutations in HIV protease can influence the effectiveness of protease inhibitors linking it to challenges in long-term HIV treatment strategies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

See full target information HIV protease

Alternative Names

HIV-1 protease, Human immunodeficiency virus protease, PR, Retropepsin

Publications (8)

Recent publications for all applications. Explore the full listand refine your search

PloS one 17:e0262477 PubMed35085286

2022

Amino acid substitutions at the HIV-1 transframe region significantly impair virus infectivity.

Applications

Unspecified application

Species

Unspecified reactive species

Fu-Hsien Yu,Kuo-Jung Huang,Chin-Tien Wang

Oncology letters 20:785-793 PubMed32566005

2020

Continuous progression of hemorrhage of sphenoid ridge meningioma causing cerebral hernia: A case report and literature review.

Applications

Unspecified application

Species

Unspecified reactive species

Song Han,Yakun Yang,Zuocheng Yang,Ning Liu,Xueling Qi,Changxiang Yan,Chunjiang Yu

Cell metabolism 29:1258-1273.e11 PubMed30930170

2019

Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Aris A Polyzos,Do Yup Lee,Rupsa Datta,Meghan Hauser,Helen Budworth,Amy Holt,Stephanie Mihalik,Pike Goldschmidt,Ken Frankel,Kelly Trego,Michael J Bennett,Jerry Vockley,Ke Xu,Enrico Gratton,Cynthia T McMurray

Frontiers in microbiology 6:1220 PubMed26583013

2015

A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors.

Applications

WB

Species

Unspecified reactive species

Satoko Matsunaga,Takashi Masaoka,Tatsuya Sawasaki,Ryo Morishita,Yasumasa Iwatani,Masashi Tatsumi,Yaeta Endo,Naoki Yamamoto,Wataru Sugiura,Akihide Ryo

Emerging microbes & infections 2:e83 PubMed26038447

2013

Slow immunological progression in HIV-1 CRF07_BC-infected injecting drug users.

Applications

WB

Species

Unspecified reactive species

Pi-Han Lin,Chung-Chih Lai,Jia-Ling Yang,Hui-Lin Huang,Ming-Siang Huang,Mao-Song Tsai,Chia-Jui Yang,Chien-Ling Cheng,Yi-Ching Su,Shu-Fang Chang,Wen-Chun Liu,Chien-Ching Hung,Sui-Yuan Chang,Shan-Chwen Chang

Retrovirology 3:58 PubMed16956392

2006

HIV-2 Protease resistance defined in yeast cells.

Applications

WB

Species

Unspecified reactive species

Najoua Ben M'Barek,Gilles Audoly,Didier Raoult,Pablo Gluschankof

Molecular biology and evolution 23:764-72 PubMed16423863

2006

Diversification and specialization of HIV protease function during in vitro evolution.

Applications

WB

Species

Unspecified reactive species

Taryn L O'Loughlin,Dina N Greene,Ichiro Matsumura

Protein science : a publication of the Protein Society 8:2686-96 PubMed10631984

2000

Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.

Applications

Unspecified application

Species

Unspecified reactive species

J Lescar,J Brynda,P Rezacova,R Stouracova,M M Riottot,V Chitarra,M Fabry,M Horejsi,J Sedlacek,G A Bentley
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com